BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opinion on Investigational Drugs 2018;27:389-406. [DOI: 10.1080/13543784.2018.1459561] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Yamamoto K, Okui R, Yamatodani A. Activation of orexinergic and histaminergic pathway involved in therapeutic effect of histamine H4 receptor antagonist against cisplatin-induced anorexia in mice. Naunyn Schmiedebergs Arch Pharmacol 2019;392:925-36. [PMID: 30919010 DOI: 10.1007/s00210-019-01646-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Azeez IA, Igado OO, Olopade JO. An overview of the orexinergic system in different animal species. Metab Brain Dis 2021. [PMID: 34224065 DOI: 10.1007/s11011-021-00761-0] [Reference Citation Analysis]
3 Akpa B, Lee K. Update on Novel Medications to Treat Narcolepsy. Curr Sleep Medicine Rep 2020;6:189-97. [DOI: 10.1007/s40675-020-00178-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Equihua-Benítez AC, Equihua-Benítez JA, Guzmán-Vásquez K, Prospero-García O, Drucker-Colín R. Orexin cell transplant reduces behavioral arrest severity in narcoleptic mice. Brain Res 2020;1745:146951. [PMID: 32531224 DOI: 10.1016/j.brainres.2020.146951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med 2020;68:97-109. [PMID: 32032921 DOI: 10.1016/j.sleep.2019.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
6 Thorpy MJ. Recently Approved and Upcoming Treatments for Narcolepsy. CNS Drugs 2020;34:9-27. [PMID: 31953791 DOI: 10.1007/s40263-019-00689-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
7 Pérez-carbonell L. Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy. Curr Treat Options Neurol 2019;21. [DOI: 10.1007/s11940-019-0595-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Choi Y, Raymer BK. Sleep modulating agents. Bioorg Med Chem Lett 2019;29:2025-33. [PMID: 31307886 DOI: 10.1016/j.bmcl.2019.06.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
10 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
11 Reading P. Cataplexy. Pract Neurol 2019;19:21-7. [PMID: 30355740 DOI: 10.1136/practneurol-2018-002001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
12 Gabryelska A, Szmyd B, Maschauer EL, Roguski A, Canham R, Morrison I, Białasiewicz P, Riha RL. Utility of measuring CSF hypocretin-1 level in patients with suspected narcolepsy. Sleep Medicine 2020;71:48-51. [DOI: 10.1016/j.sleep.2020.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Zhang D, Perrey DA, Decker AM, Langston TL, Mavanji V, Harris DL, Kotz CM, Zhang Y. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. J Med Chem 2021;64:8806-25. [PMID: 34101446 DOI: 10.1021/acs.jmedchem.1c00841] [Reference Citation Analysis]
14 Reading PJ. Update on narcolepsy. J Neurol 2019;266:1809-15. [DOI: 10.1007/s00415-019-09310-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Shariq AS, Rosenblat JD, Alageel A, Mansur RB, Rong C, Ho RC, Ragguett R, Pan Z, Brietzke E, Mcintyre RS. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2019;92:1-7. [DOI: 10.1016/j.pnpbp.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
16 Li SB, de Lecea L. The hypocretin (orexin) system: from a neural circuitry perspective. Neuropharmacology 2020;167:107993. [PMID: 32135427 DOI: 10.1016/j.neuropharm.2020.107993] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
17 Liu JJ, Mirabella VR, Pang ZP. Cell type- and pathway-specific synaptic regulation of orexin neurocircuitry. Brain Res 2020;1731:145974. [PMID: 30296428 DOI: 10.1016/j.brainres.2018.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Nepovimova E, Janockova J, Misik J, Kubik S, Stuchlik A, Vales K, Korabecny J, Mezeiova E, Dolezal R, Soukup O, Kobrlova T, Pham NL, Nguyen TD, Konecny J, Kuca K. Orexin supplementation in narcolepsy treatment: A review. Med Res Rev 2019;39:961-75. [PMID: 30426515 DOI: 10.1002/med.21550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
19 Meskill GJ, Kallweit U, Zarycranski D, Caussé C, Finance O, Ligneau X, Davis CW. Pitolisant for the treatment of cataplexy in adults with narcolepsy. Expert Opinion on Orphan Drugs. [DOI: 10.1080/21678707.2021.2022472] [Reference Citation Analysis]
20 Takahashi T, Noriaki S, Matsumura M, Li C, Takahashi K, Nishino S. Advances in pharmaceutical treatment options for narcolepsy. Expert Opinion on Orphan Drugs 2018;6:597-610. [DOI: 10.1080/21678707.2018.1521267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Calva CB, Fadel JR. Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction. Brain Res 2020;1731:145921. [PMID: 30148983 DOI: 10.1016/j.brainres.2018.08.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
22 Murillo-Rodríguez E, Budde H, Veras AB, Rocha NB, Telles-Correia D, Monteiro D, Cid L, Yamamoto T, Machado S, Torterolo P. The Endocannabinoid System May Modulate Sleep Disorders in Aging. Curr Neuropharmacol 2020;18:97-108. [PMID: 31368874 DOI: 10.2174/1570159X17666190801155922] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]